Phase 4 N=750 The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients
Blood Loss · Tranexamic Acid · Cardiac Surgery
Primary: Postoperative Blood Loss — 290; 300; 290 ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=76 TXA Study in Major Oncologic Surgery
Tranexamic Acid · Cancer · Major Surgery
Primary: Number of Participants Who Required Transfusion — 8; 5 Participants
Phase 4 N=98 Use of Tranexamic Acid in Reduction Mammoplasty
Hematoma Postoperative · Venous Thromboembolism
Primary: Number of Breasts With Development of Hematoma — 2; 1 breasts
N/A N=42 Tranexamic Acid for The Treatment of Gastrointestinal Bleeding
Gastrointestinal Bleeding
Primary: Re-bleeding — 6; 7 Participants
Phase 4 N=29 Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery
Lumbar Spinal Stenosis · Thoracic Spinal Stenosis
Primary: Change in Hemoglobin Level From Preoperative Appointment to Postoperative Hospital Discharge — -3.2; -4.6 grams per deciliter (g/dL) — p=0.1318
Phase 3 N=87 The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery
Acetabular Fractures
Primary: Allogenic Blood Transfusion Rates — 21; 13 Participants
Phase 4 N=204 Reinfusion Drains vs Tranexamic Acid in Total Joint Arthroplasty
Total Joint Arthroplasty
Primary: Blood Transfusion — 5; 8; 1 participants
Phase 3 N=85 Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
Hereditary Angioedema
Primary: Time to Onset of Symptom Relief. — 2.0; 12.0 Hours — p=< 0.001
Phase 4 N=640 Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical
Osteoarthritis
Primary: Total Blood Loss — 323.59; 271.22 ml
Phase 4 N=955 Prospective Trial of Tranexamic Acid in Cardiac Surgery
C.Surgical Procedure; Cardiac
Primary: Postoperative Blood Loss — 520; 490; 450 ml
Phase 3 N=114 Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery
Bleeding
Primary: Chest Tube Drainage — 200; 225; 375; 400 mL
Phase 2 N=13 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Thyroid Neoplasm
Primary: RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment — 6; 1; 1; 0 Participants
Phase 3 N=44 Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery
Coronary Artery Disease
Primary: Total Volume of Blood Loss From Mediastinal Chest Tubes at Time of Removal (Assuming the Total Volume of Loss is Blood). — 632; 789 mL — p=0.0493
N/A N=135 Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement
Primary Osteoarthritis of Knee Nos
Primary: Perioperative Blood Loss — 546.9; 475.0; 430.2; 329.2 ml — p=<0.05
Phase 4 N=32 A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population
Subdural Hematoma
Primary: Number of Participants With Medication Related (Thromboembolic) Complications — 0 Participants